In January 2024, Parexel, one of the world's largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, and the Japanese Foundation for Cancer Research (JFCR), the first and leading non-profit cancer research organization in Japan, today announced a strategic alliance to accelerate access to oncology clinical trials in Japan
This absence of metabolic disruption at chronic supra-therapeutic doses provides indirect reassurance about acute overdose safety
If you are not sure where to begin, our wellness quiz can help point you in the right direction
The control group demonstrated minimal improvement and recovery
Our dedicated Tesamorelin visceral fat research guide provides further academic context for metabolic investigators
Peeker R, Aldenborg F and Fall M: The treatment of interstitial cystitis with supratrigonal cystectomy and ileocystoplasty: Difference in outcome between classic and nonulcer disease
